THU0301 Neopterin (NPT) and soluble interleukin 2 receptor (SIL-2R) as useful markers of disease activity in juvenile idiopathic arthritis (JIA)

THU0301 Neopterin (NPT) and soluble interleukin 2 receptor (SIL-2R) as useful markers of disease activity in juvenile idiopathic arthritis (JIA)

Background JIA is the common chronic rheumatic disease in children that may continue to be active in adulthood. The new laboratory markers are needed to adjust therapy of JIA to the actual disease activity and to define group of patients with a risk of developing exacerbation. NPT (a product of guan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2013-06, Vol.71 (Suppl 3), p.257-258
Hauptverfasser: Olesinska, E., Postepski, J., Tabarkiewicz, J., Wilczynska, B., Tuszkiewicz-Misztal, E.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 258
container_issue Suppl 3
container_start_page 257
container_title Annals of the rheumatic diseases
container_volume 71
creator Olesinska, E.
Postepski, J.
Tabarkiewicz, J.
Wilczynska, B.
Tuszkiewicz-Misztal, E.
description Background JIA is the common chronic rheumatic disease in children that may continue to be active in adulthood. The new laboratory markers are needed to adjust therapy of JIA to the actual disease activity and to define group of patients with a risk of developing exacerbation. NPT (a product of guanosine triphosphate pathway) is produced by human monocytes/macrophages upon stimulation by Th1 derived INF-γ. Activated T cells release a soluble form of IL-2, considered to be en early marker for immune activation. Objectives To assess whether serum levels of NPT and sIL-2R are reliable parameters for monitoring JIA activity in the clinical practice. Methods 83 patients with active JIA (median 10.3y, 37 oligoarticular [OLIGO], 30 polyarticular [POLY], 6 systemic [soJIA], and 10 enthesitis-related–arthritis [ERA]onset) were evaluated. Of these, 38 consecutive patients were followed-up with an evaluation in remission.ACR-Pediatric variables: physician global assessment of disease activity; parent/patient assessment of overall well-being; CHAQ; number of joints with active arthritis; number of joints with limited range of motion; ESR/C-reactive protein; and additionally: duration of morning stiffness, WBC, and Hgb were collected. 25 ages- and sex- matched healthy subjects acted as controls. Serum levels of NPT and sIL-2R were measured by ELISA. Results Serum levels of NPT were significantly higher in active JIA patients (10.7±21.7 nmol/l) than in the control group (4.98±2.01nmol/l; p
doi_str_mv 10.1136/annrheumdis-2012-eular.2266
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777976875</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008660821</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1655-bd57283f91cf104d7d55b64f985fedeb16504a9ce9071efe4d82318ce1813f833</originalsourceid><addsrcrecordid>eNqVkc1u1DAUhS0EEkPhHSx1M12k2HFiO2JVjWg7w2iAMmVrOcm1xtNMEvxT0R2bvkAfkSfBYRBiy8qy73fOvdcHoVNKzill_K3ue7eDeGitz3JC8wxip915nnP-DM1owWV65uQ5mhFCWFZUXLxEr7zfpyuRVM7Q0_b6ljBCf_543MAwBnC2x_PNp-0Z1n2L_dDFugNs-1TpIN6lao4dNDCGweH5l-U6y28S63H0YGKHD9rdgfN4MDhNBdoD1k2w9zY8JBe8j_fQ28mxtcOow842WLuwczZYj-er5cXZa_TC6M7Dmz_nCbq9fL9dXGfrj1fLxcU6qykvy6xuS5FLZiraGEqKVrRlWfPCVLI00MIEkUJXDVREUDBQtDJnVDZAJWVGMnaCTo--oxu-RfBB7Yfo-tRSUSFEJbgUZaLeHanGDd47MGp0Ni35oChRUwjqnxDUFIL6HYKaQkjq7Ki2PsD3v9L0R4oLJkq1-bpQN_Lz1epy8UGtEs-PfH3Y_1ejX50Kotw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777976875</pqid></control><display><type>article</type><title>THU0301 Neopterin (NPT) and soluble interleukin 2 receptor (SIL-2R) as useful markers of disease activity in juvenile idiopathic arthritis (JIA)</title><source>BMJ Journals - NESLi2</source><creator>Olesinska, E. ; Postepski, J. ; Tabarkiewicz, J. ; Wilczynska, B. ; Tuszkiewicz-Misztal, E.</creator><creatorcontrib>Olesinska, E. ; Postepski, J. ; Tabarkiewicz, J. ; Wilczynska, B. ; Tuszkiewicz-Misztal, E.</creatorcontrib><description><![CDATA[Background JIA is the common chronic rheumatic disease in children that may continue to be active in adulthood. The new laboratory markers are needed to adjust therapy of JIA to the actual disease activity and to define group of patients with a risk of developing exacerbation. NPT (a product of guanosine triphosphate pathway) is produced by human monocytes/macrophages upon stimulation by Th1 derived INF-γ. Activated T cells release a soluble form of IL-2, considered to be en early marker for immune activation. Objectives To assess whether serum levels of NPT and sIL-2R are reliable parameters for monitoring JIA activity in the clinical practice. Methods 83 patients with active JIA (median 10.3y, 37 oligoarticular [OLIGO], 30 polyarticular [POLY], 6 systemic [soJIA], and 10 enthesitis-related–arthritis [ERA]onset) were evaluated. Of these, 38 consecutive patients were followed-up with an evaluation in remission.ACR-Pediatric variables: physician global assessment of disease activity; parent/patient assessment of overall well-being; CHAQ; number of joints with active arthritis; number of joints with limited range of motion; ESR/C-reactive protein; and additionally: duration of morning stiffness, WBC, and Hgb were collected. 25 ages- and sex- matched healthy subjects acted as controls. Serum levels of NPT and sIL-2R were measured by ELISA. Results Serum levels of NPT were significantly higher in active JIA patients (10.7±21.7 nmol/l) than in the control group (4.98±2.01nmol/l; p<0,05). In remission, serum levels of NPT decreased significantly (4.34±2.3 nmol/l; p<0,001). In soJIA the levels of NPT was significantly higher than in patients with ERA onset (28.2 nmol/l vs 4.5 nmol/l; p<0,05). The levels of NPT showed no relationship with clinical and laboratory variables neither in active disease nor in remission. Serum levels of sIL-2R were significantly higher in active JIA patients (8.9±12.8 ng/ml) than in the control group (1.8±1.6 ng/ml; p<0,001). In remission, the serum levels of sIL-2R decreased significantly (4.1±4.0 ng/ml; p=0,001). We found higher levels of sIL-2R in patients with clinically inactive disease (remission) in comparison to controls (p<0,001). In soJIA the levels of sIL-2R was significantly higher than in patients with POLY (31.4 vs 6.6; p<0,05). Serum levels of sIL-2R of patients with active disease correlated with WBC and with parent/patient assessment of overall well-being. Serum levels of sIL-2R in remission correlated with ESR and negatively with Hgb. Conclusions Serum levels of NPT and sIL-2R might be helpful markers for monitoring inflammation in JIA. To our knowledge, estimation of NPT in JIA, has not been published. NPT seems to be a useful parameter of cell-mediated immunity activation in JIA. The analysis showed serum NPT and sIL-2R concentrations differences between soJIA compared to the others. The elevated levels of sIL-2R in sera of patients in clinically remission suggest persistent activation of immune system and might be an indicator in adjusting the therapy. Longitudinal follow-up is required. This work was funded by the Polish National Science Centre (Grant N N407 0382 37). Disclosure of Interest None Declared]]></description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2012-eular.2266</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><ispartof>Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.257-258</ispartof><rights>2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/71/Suppl_3/257.3.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/71/Suppl_3/257.3.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3196,23571,27924,27925,77600,77631</link.rule.ids></links><search><creatorcontrib>Olesinska, E.</creatorcontrib><creatorcontrib>Postepski, J.</creatorcontrib><creatorcontrib>Tabarkiewicz, J.</creatorcontrib><creatorcontrib>Wilczynska, B.</creatorcontrib><creatorcontrib>Tuszkiewicz-Misztal, E.</creatorcontrib><title>THU0301 Neopterin (NPT) and soluble interleukin 2 receptor (SIL-2R) as useful markers of disease activity in juvenile idiopathic arthritis (JIA)</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description><![CDATA[Background JIA is the common chronic rheumatic disease in children that may continue to be active in adulthood. The new laboratory markers are needed to adjust therapy of JIA to the actual disease activity and to define group of patients with a risk of developing exacerbation. NPT (a product of guanosine triphosphate pathway) is produced by human monocytes/macrophages upon stimulation by Th1 derived INF-γ. Activated T cells release a soluble form of IL-2, considered to be en early marker for immune activation. Objectives To assess whether serum levels of NPT and sIL-2R are reliable parameters for monitoring JIA activity in the clinical practice. Methods 83 patients with active JIA (median 10.3y, 37 oligoarticular [OLIGO], 30 polyarticular [POLY], 6 systemic [soJIA], and 10 enthesitis-related–arthritis [ERA]onset) were evaluated. Of these, 38 consecutive patients were followed-up with an evaluation in remission.ACR-Pediatric variables: physician global assessment of disease activity; parent/patient assessment of overall well-being; CHAQ; number of joints with active arthritis; number of joints with limited range of motion; ESR/C-reactive protein; and additionally: duration of morning stiffness, WBC, and Hgb were collected. 25 ages- and sex- matched healthy subjects acted as controls. Serum levels of NPT and sIL-2R were measured by ELISA. Results Serum levels of NPT were significantly higher in active JIA patients (10.7±21.7 nmol/l) than in the control group (4.98±2.01nmol/l; p<0,05). In remission, serum levels of NPT decreased significantly (4.34±2.3 nmol/l; p<0,001). In soJIA the levels of NPT was significantly higher than in patients with ERA onset (28.2 nmol/l vs 4.5 nmol/l; p<0,05). The levels of NPT showed no relationship with clinical and laboratory variables neither in active disease nor in remission. Serum levels of sIL-2R were significantly higher in active JIA patients (8.9±12.8 ng/ml) than in the control group (1.8±1.6 ng/ml; p<0,001). In remission, the serum levels of sIL-2R decreased significantly (4.1±4.0 ng/ml; p=0,001). We found higher levels of sIL-2R in patients with clinically inactive disease (remission) in comparison to controls (p<0,001). In soJIA the levels of sIL-2R was significantly higher than in patients with POLY (31.4 vs 6.6; p<0,05). Serum levels of sIL-2R of patients with active disease correlated with WBC and with parent/patient assessment of overall well-being. Serum levels of sIL-2R in remission correlated with ESR and negatively with Hgb. Conclusions Serum levels of NPT and sIL-2R might be helpful markers for monitoring inflammation in JIA. To our knowledge, estimation of NPT in JIA, has not been published. NPT seems to be a useful parameter of cell-mediated immunity activation in JIA. The analysis showed serum NPT and sIL-2R concentrations differences between soJIA compared to the others. The elevated levels of sIL-2R in sera of patients in clinically remission suggest persistent activation of immune system and might be an indicator in adjusting the therapy. Longitudinal follow-up is required. This work was funded by the Polish National Science Centre (Grant N N407 0382 37). Disclosure of Interest None Declared]]></description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkc1u1DAUhS0EEkPhHSx1M12k2HFiO2JVjWg7w2iAMmVrOcm1xtNMEvxT0R2bvkAfkSfBYRBiy8qy73fOvdcHoVNKzill_K3ue7eDeGitz3JC8wxip915nnP-DM1owWV65uQ5mhFCWFZUXLxEr7zfpyuRVM7Q0_b6ljBCf_543MAwBnC2x_PNp-0Z1n2L_dDFugNs-1TpIN6lao4dNDCGweH5l-U6y28S63H0YGKHD9rdgfN4MDhNBdoD1k2w9zY8JBe8j_fQ28mxtcOow842WLuwczZYj-er5cXZa_TC6M7Dmz_nCbq9fL9dXGfrj1fLxcU6qykvy6xuS5FLZiraGEqKVrRlWfPCVLI00MIEkUJXDVREUDBQtDJnVDZAJWVGMnaCTo--oxu-RfBB7Yfo-tRSUSFEJbgUZaLeHanGDd47MGp0Ni35oChRUwjqnxDUFIL6HYKaQkjq7Ki2PsD3v9L0R4oLJkq1-bpQN_Lz1epy8UGtEs-PfH3Y_1ejX50Kotw</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Olesinska, E.</creator><creator>Postepski, J.</creator><creator>Tabarkiewicz, J.</creator><creator>Wilczynska, B.</creator><creator>Tuszkiewicz-Misztal, E.</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201306</creationdate><title>THU0301 Neopterin (NPT) and soluble interleukin 2 receptor (SIL-2R) as useful markers of disease activity in juvenile idiopathic arthritis (JIA)</title><author>Olesinska, E. ; Postepski, J. ; Tabarkiewicz, J. ; Wilczynska, B. ; Tuszkiewicz-Misztal, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1655-bd57283f91cf104d7d55b64f985fedeb16504a9ce9071efe4d82318ce1813f833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Olesinska, E.</creatorcontrib><creatorcontrib>Postepski, J.</creatorcontrib><creatorcontrib>Tabarkiewicz, J.</creatorcontrib><creatorcontrib>Wilczynska, B.</creatorcontrib><creatorcontrib>Tuszkiewicz-Misztal, E.</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Olesinska, E.</au><au>Postepski, J.</au><au>Tabarkiewicz, J.</au><au>Wilczynska, B.</au><au>Tuszkiewicz-Misztal, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>THU0301 Neopterin (NPT) and soluble interleukin 2 receptor (SIL-2R) as useful markers of disease activity in juvenile idiopathic arthritis (JIA)</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2013-06</date><risdate>2013</risdate><volume>71</volume><issue>Suppl 3</issue><spage>257</spage><epage>258</epage><pages>257-258</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract><![CDATA[Background JIA is the common chronic rheumatic disease in children that may continue to be active in adulthood. The new laboratory markers are needed to adjust therapy of JIA to the actual disease activity and to define group of patients with a risk of developing exacerbation. NPT (a product of guanosine triphosphate pathway) is produced by human monocytes/macrophages upon stimulation by Th1 derived INF-γ. Activated T cells release a soluble form of IL-2, considered to be en early marker for immune activation. Objectives To assess whether serum levels of NPT and sIL-2R are reliable parameters for monitoring JIA activity in the clinical practice. Methods 83 patients with active JIA (median 10.3y, 37 oligoarticular [OLIGO], 30 polyarticular [POLY], 6 systemic [soJIA], and 10 enthesitis-related–arthritis [ERA]onset) were evaluated. Of these, 38 consecutive patients were followed-up with an evaluation in remission.ACR-Pediatric variables: physician global assessment of disease activity; parent/patient assessment of overall well-being; CHAQ; number of joints with active arthritis; number of joints with limited range of motion; ESR/C-reactive protein; and additionally: duration of morning stiffness, WBC, and Hgb were collected. 25 ages- and sex- matched healthy subjects acted as controls. Serum levels of NPT and sIL-2R were measured by ELISA. Results Serum levels of NPT were significantly higher in active JIA patients (10.7±21.7 nmol/l) than in the control group (4.98±2.01nmol/l; p<0,05). In remission, serum levels of NPT decreased significantly (4.34±2.3 nmol/l; p<0,001). In soJIA the levels of NPT was significantly higher than in patients with ERA onset (28.2 nmol/l vs 4.5 nmol/l; p<0,05). The levels of NPT showed no relationship with clinical and laboratory variables neither in active disease nor in remission. Serum levels of sIL-2R were significantly higher in active JIA patients (8.9±12.8 ng/ml) than in the control group (1.8±1.6 ng/ml; p<0,001). In remission, the serum levels of sIL-2R decreased significantly (4.1±4.0 ng/ml; p=0,001). We found higher levels of sIL-2R in patients with clinically inactive disease (remission) in comparison to controls (p<0,001). In soJIA the levels of sIL-2R was significantly higher than in patients with POLY (31.4 vs 6.6; p<0,05). Serum levels of sIL-2R of patients with active disease correlated with WBC and with parent/patient assessment of overall well-being. Serum levels of sIL-2R in remission correlated with ESR and negatively with Hgb. Conclusions Serum levels of NPT and sIL-2R might be helpful markers for monitoring inflammation in JIA. To our knowledge, estimation of NPT in JIA, has not been published. NPT seems to be a useful parameter of cell-mediated immunity activation in JIA. The analysis showed serum NPT and sIL-2R concentrations differences between soJIA compared to the others. The elevated levels of sIL-2R in sera of patients in clinically remission suggest persistent activation of immune system and might be an indicator in adjusting the therapy. Longitudinal follow-up is required. This work was funded by the Polish National Science Centre (Grant N N407 0382 37). Disclosure of Interest None Declared]]></abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><doi>10.1136/annrheumdis-2012-eular.2266</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.257-258
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1777976875
source BMJ Journals - NESLi2
title THU0301 Neopterin (NPT) and soluble interleukin 2 receptor (SIL-2R) as useful markers of disease activity in juvenile idiopathic arthritis (JIA)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T08%3A30%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=THU0301%E2%80%85Neopterin%20(NPT)%20and%20soluble%20interleukin%202%20receptor%20(SIL-2R)%20as%20useful%20markers%20of%20disease%20activity%20in%20juvenile%20idiopathic%20arthritis%20(JIA)&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Olesinska,%20E.&rft.date=2013-06&rft.volume=71&rft.issue=Suppl%203&rft.spage=257&rft.epage=258&rft.pages=257-258&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2012-eular.2266&rft_dat=%3Cproquest_cross%3E4008660821%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777976875&rft_id=info:pmid/&rfr_iscdi=true